Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combined With Abraxane and Cisplatin in Resectable Esophageal Squamous Cell Cancer
NCT05828381Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
01
Overview
A Phase 2 trial of envafolimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Fujian Medical University Union Hospital. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
envafolimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05828381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828381.